Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 828

3.

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, Selby M, Otten GR, Barnett SW.

J Virol. 2000 Mar;74(6):2628-35.

4.
6.

HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses.

Marques ET Jr, Chikhlikar P, de Arruda LB, Leao IC, Lu Y, Wong J, Chen JS, Byrne B, August JT.

J Biol Chem. 2003 Sep 26;278(39):37926-36. Epub 2003 Jun 24.

8.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
9.
11.

Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.

Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, Kojima A, Nagai Y, Iwamoto A, Matsuda Z, Ariyoshi K.

J Virol. 2004 Feb;78(3):1324-32.

12.

Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost.

Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM.

Vaccine. 2001 Apr 6;19(20-22):2803-11.

PMID:
11282190
13.

Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.

Kuate S, Stahl-Hennig C, Stoiber H, Nchinda G, Floto A, Franz M, Sauermann U, Bredl S, Deml L, Ignatius R, Norley S, Racz P, Tenner-Racz K, Steinman RM, Wagner R, Uberla K.

Virology. 2006 Jul 20;351(1):133-44. Epub 2006 Apr 17.

15.

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.

Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J.

Vaccine. 1995 Jun;13(9):857-65.

PMID:
7483809
16.
18.
19.
20.

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles.

Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, Wolf H.

Virology. 1996 Jun 1;220(1):128-40.

Supplemental Content

Support Center